Lesion-directed antibiotics in dry dosage forms for the treatment of shallow ulcers of the oral mucosa
Patent 5981499 Issued on November 9, 1999. Estimated Expiration Date: February 20, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
514/29, The hetero ring has exactly 13 ring carbons (e.g., erythromycin, etc.)424/641, Zinc424/653, Bismuth424/692, Magnesium hydroxide or oxide514/31, The hetero ring has 20 or more ring carbons (e.g., nystatin, etc.)514/39, Three or more saccharide radicals (e.g., neomycin, etc.)514/152, 3,10-dihydroxy-2-naphthacene carboxamide or derivative (e.g., tetracycline, etc.) DOAI514/192, 1-thia-4-aza-bicyclo (3.2.0) heptane ring containing (including dehydrogenated) (e.g., penicillins, etc.)514/2001-thia-5-aza-bicyclo (4.2.0) octane ring containing (including dehydrogenated) (e.g., cephalosporins, etc.)
The invention provides a medicament for topically treating aphthous ulcers in the oral mucosa, and methods of use. The medicament comprises a troche or powder comprising a dry dosage of one or more antibiotics and, preferably, one or more polyvalent metal compounds. The troche or powder is directly applied to the aphthous ulcer and dissolves in saliva, within about 5 to about 15 minutes, thereby directly delivering a supratherapeutic dosage of the antibiotic to the ulcerated oral tissue. Further, in a preferred embodiment the troche/powder directly delivers a therapeutically high concentration of a polyvalent metal compound in suspension to the aphthous ulcer, thereby forming a protective barrier over the ulcerated oral tissue.
Other References
Spark, R.P., Fatal Anaphylaxis due to oral penicillin, Am. J. Clin. Path. 56, 1971, 407-411
Chain, E., et al., Penicillin as a chemotherapeutic agent, Lancet 2, 1940, 226-228
Abraham, E.P., et al., Further observations on penicillin, Lancet 2, 1941, 177-189
Weinstein, L., Clinical and bacteriologic studies of the . . . gram-negative bacilli, New Eng. J. Med. 271, 1964, 525-532
Grzesiak, J.J. and Pierschbacher, M.D., Shifts in the concentrations . . . migratory response, J. Clin. Invest. 95, 1995, 227-233
Drug Information 97, published by Authority of the Board of the American Society of Health-System Pharmacists, 251-252 (1997)
The Dispensatory of the USA, 25th Ed. based on 15th Rev. of US Pharmacopoeia, 10th Ed. of Nat. Formulary, Britsh Pharmacopoeia, 1953, 1st Ed. of Intl. Pharmacopoeia, Vo. I & II, 1955, 1007-1008
The Use of Antibiotics, edited by A. Kucers and N. Mck. Bennett, 4th Ed., 1987, pp. 16-18
Osol, et al., (Editors) The Dispensatory of the United States of America, 25th Edition Philadelphia Montreal, J.B. Lippincott Company, Part I, pp. 1006-1008, (1955)
Thoma, et al., Oral Pathology, Fifth Edition, The C.V. Mosby Company, pp. 1066-1069, (1960)
Kucers et al., The Use Of Antibiotics, J.B. Lippincott Company, Fourth Edition, pp. 16-18 (1988)
G. Darmstadt et al., "Disorders of the Mucous Membranes," Chapter 614, Nelson Textbook of Pediatrics, 15th ed., W.B. Saunders Company, pp. 1888-1889, (1996)
Goodman and Gilman's The Pharmacological Basis of Therapeutics, 6th ed., Macmillian Publishing Co., Inc., pp. 1136-1137 (1980)
Berkow (Editor), Recurrent Aphthous Stomatitis, The Merck Manual of Diagnosis and Therapy, pp. 1666-1667, 13th Ed., (1977)
L. Yikontiola, "Doxymycine-cyanoacrylate treatment of recurrent aphthous ulcers," Oral Surgery Oral Medicine Oral Pathology, pp. 329-333, (Mar. 1997)
Physicians' Desk Reference, 41 Ed., pp. 1170-1171 (1987)
Physicians' Desk Reference, 52 Ed., pp. 3097-3098 (1998)
The Merck Index, 11th Ed., pp. 894 (1989)
(Medline Abstract), Rattan J., "Sucralfate Suspension as a treatment of Recurrent Aphthous Stomatitis," From J. Itern. Med. 236(3):341-343, Sep. 1994
(Medline Abstract), Campisi G., "Sucralfate in odontostomatology. Clinical experience," Jun. 1997, From Minerve Stomatol. 46(6):297-305
(Medline Abstract), Mahdi AB, "Efficacy of Bioadhesive patches in the treatment of recurrent aphthous stomatitis," Sep. 1996, From J. Oral Pathol. Med. 25(8):416-419
(Medline Abstract), Merchant HW, "Zinc Sulfate Supplementation For Treatment of Recurring Oral Ulcers," May 1977, From South. Med. J. 70(5):559-561
(Medline Abstract), Agren MS, "Selenium Zinc, Iron and Copper Levels in Serum of Patients with Arterial and Venous Leg Ulcers," 1986, From Acta Derm Venereol 66(3):237-240
(Medline Abstract), Slomiany BL, "Sucralfate affects the susceptibility of Helicobacter Pylori to Antimicrobial Agents," 1995, From Scand J. Gastroenterol Suppl. 210:82-84
(Medline Abstract), al-Assi Mt, "Clarithromycin, Tetracycline, and Bismuth: A New Non-Metronidazole Therapy for Helicobacter Pylori Infection," Aug. 1989, From Am. J. Gastroenterol 89(8):1203-05
(Medline Abstract), Endre L., "Recurrent aphthous ulceration with zinc deficiency and cellular immune deficiency," Nov. 72, From Oral. Surg. Oral. Med. Oral. Pathol. 72(5):559-561
(Medline Abstract), Greer RO Jr., "A double-blind study of topically applied 5% amlexanox in the treatment of aphthous ulcers," Mar. 1993, From J. Oral. Maxillofac Surg. 51(3):243-248
(Medline Abstract), Phelan JA, "Major aphthous-like ulcers in patients with AIDS," Jan. 1991, From Oral Surg. Oral Med. Oral Pathol. 71(1):68-72
(Medline Abstract), Sunairi M., "Effect of anti-ulcer agents on antibiotic activity against Helicobacter pylori," Dec. 1994, From Eur. J. Gastroenterol Hepatol 6 Suppl. 1:S121-S124
(Medline Abstract), Grzesiak JJ, "Changes in the concentrations of extracellular Mg++ and Ca++ dow-regulate E-cadherin and up-rejulate . . . ," May 1995, From J. Invest Dermatol 104(5):768-774
(Medline Abstract), Rosch W, "Therapy of peptic ulcer and chronic gastritis with bismuth salts," Sep. 1987, From Z. Gastroenterol 25 Suppl. 4:34-40
(Medline Abstract), Cox RD, "Evaluation of intravenous magnesium sulfate for the treatment of hydrofluoric acid burns", 1994, From J. Toxicol Clin. Toxicol 32(2):123-126
(Medline Abstract), Harris JC, "Comparative efficacy of injectable calcium and magnesium salts in the therapy of hydrofluoric acid burns," Sep. 1981, From Clin. Toxicol. 18(9):1027-1032
(Medline Abstract), Jacobson JM, "Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infections . . . ," May 22, 1997, From N. Engl. J. Med. 336(21):1487-1493
Grzesiak et al., "Shifts in the Concentrations . . . Migratory Response," J. Clin. Invest., vol. 95, pp. 227-233 (1995)
Tone et al., "Influence of Zinc Deficiency on Phagocytosis in Mice," Kitasato Arch. of Exp. Med., vol. 64, No. 4, pp. 263-269 (1991
February 20, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
